Why Insilico Medicine won
Insilico Medicine is recognized as the 2026 Best Company in AI Drug Discovery at the AI Horizon Awards for its generative AI drug discovery and development (Pharma.AI platform).
Its AI work also spans AI target identification (PandaOmics), AI molecule design (Chemistry42) and clinical trial outcome prediction (inClinico).
About Insilico Medicine
Founded in 2014 by Alex Zhavoronkov, Insilico Medicine is a clinical-stage biotech company powered by generative AI. Its Pharma.AI platform identifies new disease targets, designs novel molecules and predicts clinical trial outcomes, and it operates robotic drug-discovery labs. The company listed on the Hong Kong Stock Exchange (HKEX: 3696) in December 2025 through InSilico Medicine Cayman TopCo. It has facilities in Cambridge/Boston, Hong Kong, New York, Montreal, Shanghai, Suzhou, Taipei and Abu Dhabi.
About the AI Horizon Awards
The AI Horizon Awards recognize companies and products doing outstanding work in artificial intelligence, from AI agents and foundation models to healthcare, robotics and security. Winners are recognized for innovation, real-world impact and leadership in AI.
AWARDS
Show your Winner Badge
Add the official winner badge to your website, press page or email signature. It links back to this page so anyone can confirm the award.

Show your Winner Card
Share the full winner card on LinkedIn, your blog or your press page. Download the image, or copy the code to show it on your site with a link back to this page.
Download Winner Card